Embecta (NASDAQ:EMBC) Releases FY 2026 Earnings Guidance

Key Points

• FY 2026 guidance: Embecta guided EPS of 1.55–1.75 and revenue of $1.0 billion, well below consensus estimates of EPS 2.82 and revenue $1.1 billion.
• Recent results and valuation: the company missed Q results with EPS of $0.27 versus $0.42 expected and revenue of $221.8 million versus $235.7 million, and the stock has a market cap of $547.8 million and a P/E of 3.9.
• Market view and ownership: analyst ratings are mixed with a MarketBeat consensus of Hold and a $18.50 price target, while institutional investors own about 93.8% of the shares.

Embecta (NASDAQ:EMBC - Get Free Report) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 1.550-1.75 for the period, compared to the consensus estimate of 2.820. The company issued revenue guidance of $1.0 billion-$1.0 billion, compared to the consensus revenue estimate of $1.1 billion.

Embecta Stock Up 0.2%

EMBC opened at $9.25 on Tuesday. The stock's fifty day moving average is $9.26 and its two-hundred day moving average is $11.27. The company has a market capitalization of $547.79 million, a P/E ratio of 3.90 and a beta of 1.09. Embecta has a 52 week low of $8.47 and a 52 week high of $15.55.

Embecta (NASDAQ:EMBC - Get Free Report) last released its quarterly earnings data on Tuesday, May 5th. The company reported $0.27 EPS for the quarter, missing the consensus estimate of $0.42 by ($0.15). The firm had revenue of $221.80 million for the quarter, compared to analysts' expectations of $235.67 million. Embecta had a negative return on equity of 26.66% and a net margin of 12.92%.Embecta has set its FY 2026 guidance at 1.550-1.75 EPS. Equities analysts anticipate that Embecta will post 2.82 earnings per share for the current year.

Analyst Upgrades and Downgrades

EMBC has been the topic of several research reports. Mizuho reduced their price objective on Embecta from $14.00 to $12.00 and set a "neutral" rating on the stock in a report on Monday, April 13th. Weiss Ratings restated a "hold (c-)" rating on shares of Embecta in a report on Wednesday, January 21st. Wall Street Zen upgraded Embecta from a "buy" rating to a "strong-buy" rating in a report on Saturday, March 7th. Finally, BTIG Research restated a "buy" rating and set a $25.00 price objective on shares of Embecta in a report on Friday, February 6th. One investment analyst has rated the stock with a Buy rating and three have given a Hold rating to the company's stock. According to MarketBeat, Embecta has an average rating of "Hold" and a consensus price target of $18.50.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Brooklyn Investment Group increased its holdings in shares of Embecta by 5.9% in the 4th quarter. Brooklyn Investment Group now owns 19,736 shares of the company's stock valued at $234,000 after acquiring an additional 1,098 shares during the period. The Manufacturers Life Insurance Company increased its holdings in shares of Embecta by 5.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 21,589 shares of the company's stock valued at $209,000 after acquiring an additional 1,110 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Embecta by 2.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,323 shares of the company's stock valued at $629,000 after acquiring an additional 1,159 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Embecta by 1.0% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 150,271 shares of the company's stock valued at $1,785,000 after acquiring an additional 1,520 shares during the period. Finally, Larson Financial Group LLC increased its holdings in shares of Embecta by 368.6% in the 3rd quarter. Larson Financial Group LLC now owns 2,001 shares of the company's stock valued at $28,000 after acquiring an additional 1,574 shares during the period. 93.83% of the stock is currently owned by hedge funds and other institutional investors.

About Embecta

Embecta Corp NASDAQ: EMBC is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.